Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
BB
Virtus Biotech ETF
BBP
Volume
30.41K
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
BB
BBP
BB
Virtus Biotech ETF
BBP
News
·
Why Is ImmunityBio Stock Soaring On Friday?
AUM
N/A
Volume
30.41K
Yield
0.47%
Chart
Earnings
News
About
Insider
Filings
Why Is ImmunityBio Stock Soaring On Friday?
ImmunityBio (IBRX) shares surged 10.60% on Friday after the company completed manufacturing engineering programs for its NK cell therapy platform. The NK2022 and NK2023 programs demonstrated safe and reproducible production of up to five billion NK cells from a single collection with no serious adverse events. Additionally, the FDA acknowledged receipt of ImmunityBio's resubmission for ANKTIVA in treating BCG-unresponsive bladder cancer, with analysts maintaining a Buy rating and $12.57 average price target.
Benzinga · Mar 13, 2026
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion
Merck & Co. has agreed to acquire SpringWorks Therapeutics for around $4 billion, a 26% premium over SpringWorks' 20-day average price. The acquisition will boost Merck's revenue and expand its U.S. healthcare presence, particularly in rare tumor treatments.
Benzinga · Apr 28, 2025
Gate Q1 2025 Transparency Report: Sustained Leadership in Crypto Markets with Multiple Metrics Hitting New Highs
Gate.io, a leading global digital asset platform, has released its Q1 2025 Transparency Report, showcasing impressive growth across multiple business segments, including trading volume, token performance, security, and product offerings.
GlobeNewswire Inc. · Apr 10, 2025
4 Best-Performing Sector ETFs of June
We have highlighted four top-performing ETFs from different sectors that have led the way in June.
Zacks Investment Research · Jul 1, 2024
Biotech ETFs Stage Solid Comeback at the Start of 2024
The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.
Zacks Investment Research · Jan 9, 2024
5 Least-Hurt Biotech ETFs of the Last Week
Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.
Zacks Investment Research · Feb 15, 2023
2 Sector ETFs Hovering Around a 52-Week High
We all know that Wall Street is shattered this year. Still, two sectors -- Biotech and Aerospace -- have recently hit a 52-week high.
Zacks Investment Research · Dec 6, 2022
5 Best Areas of Q3 of 2022 & Their Top ETFs
These ETF areas won in the third quarter of 2022.
Zacks Investment Research · Sep 27, 2022
Biotech & Crypto -- Best ETF Areas of Last Week
Biotech and cryptocurrency -- two ETF areas outperformed last week.
Zacks Investment Research · Aug 8, 2022
Biotech Wins Last Week: 5 Best ETFs
The biotech corner of the broad healthcare sector outperformed last week on speculation over a takeover bid for Global Blood Therapeutics.
Zacks Investment Research · Aug 8, 2022
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
BB
BBP
Virtus Biotech ETF
Buy
Sell
Market
Limit
Soon
BBP
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any BBP yet.
Related Tickers
Earnings